Ann Rhoads - Globus Medical Independent Director

GMED Stock  USD 53.64  0.58  1.09%   

Director

Ms. Ann D. Rhoads serves as Independent Director of the Company. Ms. Rhoads currently serves as Chief Financial Officer of Forty Seven, Inc., a clinicalstage company focused on developing checkpoint therapies to activate macrophages in the fight against cancer. Previously, Ms. Rhoads was Executive Vice President and Chief Financial Officer of Zogenix, Inc., a pharmaceutical company, from March 2010 through January 2017. From 2000 through the end of 2009, Ms. Rhoads served as the Chief Financial Officer of Premier, Inc., a healthcare supply management company. From 1998 to 2000, she was Vice President, Strategic Initiatives at Premier, Inc., and from 1993 to 1998, she was a Vice President of The Sprout Group, an institutional VC firm. Ms. Rhoads holds a B.S. in Finance from the University of Arkansas and an M.B.A. from the Harvard Business School. Ms. Rhoads also serves on the board of directors, as chairman of the audit committee and as a member of the compensation committee of Evoke Pharma, Inc. . Ms. Rhoads also previously served on the board of directors of Iridex Corporation from 2017 to 2018 and Novellus Systems, Inc. from 2003 until 2012. Ms. Rhoads experience as the chief financial officer of a publiclytraded pharmaceutical company and as a member of the board of directors of a publiclytraded company brings to our Board of Directors and the committees of our Board of Directors valuable financial skills and expertise, which qualify her to serve as an audit committee financial expert on our Audit Committee, and significant executive management experience and leadership skills, as well as a strong understanding of corporate governance principles. since 2011.
Age 55
Tenure 13 years
Professional MarksMBA
Address 2560 General Armistead Avenue, Audubon, PA, United States, 19403
Phone610 930 1800
Webhttps://www.globusmedical.com
Rhoads also previously served on the board of directors of Novellus Systems, Inc. from 2003 until 2012.

Globus Medical Management Efficiency

The company has return on total asset (ROA) of 0.0477 % which means that it generated a profit of $0.0477 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0421 %, meaning that it created $0.0421 on every $100 dollars invested by stockholders. Globus Medical's management efficiency ratios could be used to measure how well Globus Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of March 29, 2024, Return On Capital Employed is expected to decline to 0.03. In addition to that, Return On Assets is expected to decline to 0.02. At present, Globus Medical's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 82.5 M, whereas Fixed Asset Turnover is forecasted to decline to 2.30.
The company currently holds 520.4 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Globus Medical has a current ratio of 5.98, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Globus Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Globus Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Globus Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Globus to invest in growth at high rates of return. When we think about Globus Medical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Doron BirgerMedigus Ltd ADR
66
Anat NaschitzMedigus Ltd ADR
N/A
Kieran GallahueEdwards Lifesciences Corp
57
Jay SkylerDexCom Inc
71
Yair RabinovitchMedigus Ltd ADR
67
Ori HershkovitzMedigus Ltd ADR
39
Nicholas ValerianiEdwards Lifesciences Corp
64
Barbara McNeilEdwards Lifesciences Corp
74
John CardisEdwards Lifesciences Corp
73
Eitan MachoverMedigus Ltd ADR
55
Martha MarshEdwards Lifesciences Corp
72
Shervin KorangyMotus GI Holdings
43
Jeremy StarkweatherMedigus Ltd ADR
42
Efrat VenkertMedigus Ltd ADR
46
Leslie HeiszEdwards Lifesciences Corp
60
Erez HaimovitzMedigus Ltd ADR
N/A
Nicholas AugustinosDexCom Inc
59
Yair RabinowitchMedigus Ltd ADR
71
Eric TopolDexCom Inc
63
Yuval YanaiMedigus Ltd ADR
65
Gary PrudenMotus GI Holdings
56
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania. Globus Medical operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 2400 people. Globus Medical (GMED) is traded on New York Stock Exchange in USA. It is located in 2560 General Armistead Avenue, Audubon, PA, United States, 19403 and employs 5,000 people. Globus Medical is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Globus Medical Leadership Team

Elected by the shareholders, the Globus Medical's board of directors comprises two types of representatives: Globus Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Globus. The board's role is to monitor Globus Medical's management team and ensure that shareholders' interests are well served. Globus Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Globus Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Steve Zarrilli, Independent Director
David Paul, Co-Founder, Chairman, CEO, Chairman of Compensation Committee and Chairman of Nominating and Corporate Governance Committee
Eric Schwartz, Senior Vice President General Counsel
Mike Reeder, Ex Officer
Ann Rhoads, Independent Director
Robert Douglas, Independent Director
Andrew Murphy, Group President Commercial Operations
Steven Payne, VP Controller
Anthony Williams, Senior Vice President General Counsel
Kelly Esq, General VP
Kelly Huller, Senior Vice President General Counsel, Corporate Secretary
Stephen Zarrilli, Independent Director
Robert Liptak, Independent Director
James Tobin, Independent Director
Kurt Wheeler, Independent Director
Brian Kearns, Senior Relations
Brett Murphy, Group President of Commercial Operations
Richard Holifield, Ex Officer
Daniel Lemaitre, Independent Director
John Dowling, Ex Officer
Keith Pfeil, Chief Financial Officer, Senior Vice President
David Demski, Group President of Emerging Technologies, Director and Member of Nominating and Corporate Governance Committee
Daniel Scavilla, Executive Vice President, Chief Commercial Officer and President - Trauma
David Davidar, Co-Founder, Sr. VP of Operations and Director

Globus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Globus Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Globus Medical Investors Sentiment

The influence of Globus Medical's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Globus. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Globus Medical's public news can be used to forecast risks associated with an investment in Globus. The trend in average sentiment can be used to explain how an investor holding Globus can time the market purely based on public headlines and social activities around Globus Medical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Globus Medical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Globus Medical's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Globus Medical's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Globus Medical.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Globus Medical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Globus Medical's short interest history, or implied volatility extrapolated from Globus Medical options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Globus Medical is a strong investment it is important to analyze Globus Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Globus Medical's future performance. For an informed investment choice regarding Globus Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Globus Medical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
For information on how to trade Globus Stock refer to our How to Trade Globus Stock guide.
Note that the Globus Medical information on this page should be used as a complementary analysis to other Globus Medical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Complementary Tools for Globus Stock analysis

When running Globus Medical's price analysis, check to measure Globus Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Globus Medical is operating at the current time. Most of Globus Medical's value examination focuses on studying past and present price action to predict the probability of Globus Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Globus Medical's price. Additionally, you may evaluate how the addition of Globus Medical to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Is Globus Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Globus Medical. If investors know Globus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Globus Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.79)
Earnings Share
1.07
Revenue Per Share
13.87
Quarterly Revenue Growth
1.246
Return On Assets
0.0477
The market value of Globus Medical is measured differently than its book value, which is the value of Globus that is recorded on the company's balance sheet. Investors also form their own opinion of Globus Medical's value that differs from its market value or its book value, called intrinsic value, which is Globus Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Globus Medical's market value can be influenced by many factors that don't directly affect Globus Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Globus Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Globus Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Globus Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.